Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.44 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978645 | 1.00 | TK1 (0.44) | TK1RNASE1NT5MTK2DHFR | |
| SCHEMBL14968221 | 0.88 | TK1 (0.43) | TK1RNASE1NT5MTK2DHFR | |
| SCHEMBL9978644 | 0.88 | TK1 (0.43) | TK1RNASE1NT5MTK2DHFR | |
| SCHEMBL19660825 | 0.87 | TK1 (0.45) | TK1RNASE1TK2 | |
| SCHEMBL19953995 | 0.86 | TK1 (0.44) | TK1RNASE1TK2 | |
| SCHEMBL409820 | 0.86 | RNASE1 (0.50) | TK1RNASE1TK2 | |
| SCHEMBL441127 | 0.86 | RNASE1 (0.50) | TK1RNASE1TK2 | |
| SCHEMBL27157713 | 0.83 | TYMP (0.48) | TK1RNASE1NT5MTK2 | |
| SCHEMBL23086299 | 0.82 | TK1 (0.42) | TK1RNASE1NT5MTK2DHFR | |
| SCHEMBL29824595 | 0.82 | TK1 (0.42) | TK1RNASE1NT5MTK2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3858847-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | Sarepta Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-2785729-B1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-10577605-B2 | Induced exon inclusion in spinal muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-06-13 | — | — | US | disclosed |
| US-10066228-B2 | Oligonucleotides for treating expanded repeat diseases | SAREPTA THERAPEUTICS, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-9944926-B2 | Induced exon inclusion in spinal muscle atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329772-A1 | INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140303238-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| EP-2780299-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | Sarepta Therapeutics, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | TK1 2064/4885RNASE1 171/4885NT5M 1154/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885RNASE1 56/4885NT5M 3073/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | TK1 418/4885RNASE1 56/4885NT5M 3073/4885 |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | UTRN, SMN1; SMN2, MTPN | TK1 2294/4885RNASE1 145/4885NT5M 2788/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | TK1 418/4885RNASE1 56/4885NT5M 3073/4885 |
| US-10905709-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | TK1 3067/4885RNASE1 407/4885NT5M 3072/4885 |
| US-11674139-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | TK1 2064/4885RNASE1 171/4885NT5M 1154/4885 |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | TK1 3067/4885RNASE1 407/4885NT5M 3072/4885 |
| US-10066228-B2 | Oligonucleotides for treating expanded repeat diseases | HTT, UPF1, TARDBP | TK1 2064/4885RNASE1 171/4885NT5M 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.